ArQule, Inc. (NASDAQ:ARQL) posted its earnings results on Friday, August 4th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01, Bloomberg Earnings reports. ArQule had a negative return on equity of 135.68% and a negative net margin of 482.44%. During the same quarter last year, the business posted ($0.07) EPS.

ArQule (ARQL) traded up 1.94% on Monday, hitting $1.05. The stock had a trading volume of 43,385 shares. ArQule has a 12-month low of $0.92 and a 12-month high of $1.82. The company’s 50 day moving average is $1.21 and its 200 day moving average is $1.19. The firm’s market cap is $74.70 million.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/14/arqule-inc-arql-releases-quarterly-earnings-results-beats-expectations-by-0-01-eps-updated.html.

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC increased its stake in shares of ArQule by 1.4% in the fourth quarter. Renaissance Technologies LLC now owns 2,017,600 shares of the biotechnology company’s stock valued at $2,542,000 after buying an additional 26,900 shares in the last quarter. Northern Trust Corp increased its stake in shares of ArQule by 0.9% in the second quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 1,385 shares in the last quarter. Finally, First Eagle Investment Management LLC increased its stake in shares of ArQule by 8.6% in the second quarter. First Eagle Investment Management LLC now owns 11,847,575 shares of the biotechnology company’s stock valued at $14,691,000 after buying an additional 934,842 shares in the last quarter. 61.70% of the stock is currently owned by institutional investors.

Separately, Zacks Investment Research lowered ArQule from a “hold” rating to a “sell” rating in a research report on Thursday, May 4th.

About ArQule

ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.

Earnings History for ArQule (NASDAQ:ARQL)

Receive News & Stock Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related stocks with our FREE daily email newsletter.